Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab, Disitamab Vedotin, and Pyrotinib in HER2+ Advanced Colorectal Cancer
NCT05350917Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2022
- Primary completion
- Jun 2025
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, disitamab vedotin and pyrotinib in colorectal cancer (CRC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Objective Response Rate up to 24 months. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
tislelizumabdisitamab vedotinpyrotinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05350917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05350917.